Latest news with #CourtneyBreen
Business Insider
4 days ago
- Business
- Business Insider
Bernstein Keeps Their Hold Rating on Pfizer (PFE)
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. Confident Investing Starts Here: Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Moderna. According to TipRanks, Breen has an average return of -0.1% and a 27.78% success rate on recommended stocks. In addition to Bernstein, Pfizer also received a Hold from Berenberg Bank's Kerry Holford in a report issued on May 29. However, on May 30, DBS maintained a Buy rating on Pfizer (NYSE: PFE). The company has a one-year high of $31.54 and a one-year low of $20.92. Currently, Pfizer has an average volume of 53.81M. Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year. Most recently, in March 2025, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
Yahoo
16-04-2025
- Business
- Yahoo
Why Pfizer Stock Topped the Market on Tuesday
On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (NYSE: PFE). Somewhat counterintuitively, this week's rise came after the company announced it was ending the development of a drug in a very hot product category. On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip. Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug danuglipron. This occurred after a patient suffered a liver injury during the testing of the medication. Yet Pfizer watchers are well aware that the large and well-resourced company doesn't only have one pony in the race. It has a different treatment in its pipeline, PF-07976016, that's based on a different mechanism and is currently undergoing phase 2 clinical trials. One analyst tracking the pharmaceutical stock didn't hesitate to point in a new research note published Tuesday morning that the company still has options. Bernstein SocGen's Courtney Breen wrote in her analysis, according to reports, that Pfizer will likely turn to its tried-and-true strategy of building up its pipeline with mergers and acquisitions, and/or licensing of products developed by peers. Investors can be quite a hardy bunch, and collectively they seem to be shrugging off what many would consider a major setback in the lab with danuglipron. That being said, it is a setback, and Pfizer hasn't been a pharmaceutical pace-setter since the days of its Comirnaty vaccine during the coronavirus pandemic. The market is likely to start getting more impatient with the company soon. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $502,231!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $678,552!* Now, it's worth noting Stock Advisor's total average return is 800% — a market-crushing outperformance compared to 156% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of April 14, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool has a disclosure policy. Why Pfizer Stock Topped the Market on Tuesday was originally published by The Motley Fool Sign in to access your portfolio
Globe and Mail
15-04-2025
- Business
- Globe and Mail
Pfizer (PFE) Gets a Hold from Bernstein
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The company's shares closed yesterday at $22.12. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Breen covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Pfizer, and Merck & Company. According to TipRanks, Breen has an average return of -3.1% and a 25.00% success rate on recommended stocks. In addition to Bernstein, Pfizer also received a Hold from Citi's Geoff Meacham in a report issued today. However, yesterday, Jefferies maintained a Buy rating on Pfizer (NYSE: PFE). Based on Pfizer's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $17.76 billion and a net profit of $410 million. In comparison, last year the company earned a revenue of $14.25 billion and had a GAAP net loss of $3.34 billion Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock. Last month, JENNIFER B. DAMICO, the SVP & Controller of PFE sold 3,249.00 shares for a total of $84,373.90.
